

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 6 :</b> <b>C12Q 1/68, C12P 19/34, C07H 21/04</b>		<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 96/36735</b> <b>(43) International Publication Date:</b> 21 November 1996 (21.11.96)		
<b>(21) International Application Number:</b> PCT/US96/07116 <b>(22) International Filing Date:</b> 13 May 1996 (13.05.96)		<b>(81) Designated States:</b> CA, CN, JP, European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).			
<b>(30) Priority Data:</b> 08/445,289 19 May 1995 (19.05.95) US		<b>Published</b> <i>With international search report.</i>			
<b>(71) Applicant:</b> AMERICAN TYPE CULTURE COLLECTION [US/US]; 12301 Parklawn Drive, Rockville, MD 20852 (US).					
<b>(72) Inventor:</b> ROBLIN, Richard, O., III; 605 West 2nd Street, Frederick, MD 21701 (US).					
<b>(74) Agent:</b> WHITHAM, Michael, E.; Whitham, Curtis, Whitham & McGinn, Reston International Center, Suite 900, 11800 Sunrise Valley Drive, Reston, VA 20191 (US).					
<b>(54) Title:</b> A MYCOPLASMA POLYMERASE CHAIN REACTION TESTING SYSTEM USING A SET OF MIXED AND SINGLE SEQUENCE PRIMERS					
<b>(57) Abstract</b> <p>The present invention relates to an enhanced system for specific, sensitive and rapid detection of the presence and identification of the specific mycoplasma contained in a sample of nucleic acid, wherein the sample nucleic acid is amplified using nested PCR which uses a mixture of first stage and second stage primers, each comprising at least one single sequence and at least one mixed sequence primer.</p>					

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NE	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Liechtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

# A MYCOPLASMA POLYMERASE CHAIN REACTION TESTING SYSTEM USING A SET OF MIXED AND SINGLE SEQUENCE PRIMERS

## DESCRIPTION

5

### BACKGROUND OF THE INVENTION

#### *Field of the Invention*

This invention relates to a mycoplasma detection system using a "nested" (two-stage) polymerase chain reaction (PCR) that uses a mixture of "mixed sequence" and "single sequence" oligonucleotide primers. In the first PCR 10 reaction, a mixture of "outer" or first stage primers is used to amplify a specific region of the mycoplasma DNA. The amplicons from this first reaction serve as the template for a second reaction, wherein the amplicons are further amplified in the second reaction using a mixture of "inner" or second stage primers. This system accurately and consistently detects a number of commonly encountered 15 mycoplasma contaminants in cell cultures, viral stocks and biopharmaceutical reagents, including the contaminant often undetected *Acholeplasma laidlawii*, and further detects Mycoplasma-Like Organisms (MLO). The system is very sensitive and very specific, showing almost no cross-reaction with related bacteria and mammalian cells.

20

#### *Background Description*

Mycoplasma are prokaryotic microorganisms belonging to the class *Mollicutes*. About 100 mycoplasma species are currently known and they are classified into six genera. Mycoplasma lack a cell wall and are almost always

found in close contact with eukaryotic cells. Many mycoplasma are pathogens.

A wide variety of cell cultures can be contaminated with mycoplasma, posing a problem for many scientists. In addition, virus stocks, live virus vaccines and biopharmaceutical drugs that are prepared using animal cell cultures 5 may become contaminated with mycoplasma.

Mycoplasma are prevalent in continuously growing cell lines. The contamination by mycoplasma has been a serious problem, and adversely affects experimental research. Studies have shown that cell cultures are frequently infected up to 5-87% with mycoplasma. [Rawadi and Dussurget, "Advances in 10 PCR-based Detection of Mycoplasmas Contaminating Cell Cultures", PCR Methods and Applications, 4, pp. 199-208 (1995)]. In addition, in some cases it is difficult to eliminate mycoplasmas from contaminated cell cultures.

Contamination by mycoplasma cannot be detected by viewing cultures. In addition, mycoplasma are not always detectable with macroscopic alteration of the 15 cells or media. Many mycoplasma contaminants grow slowly and do not destroy the host cells. However, adverse effects of mycoplasma contamination, such as changes in metabolism; growth; viability; DNA, RNA and protein synthesis; pH shift; and morphology; etc.; are still numerous. Another problem associated with mycoplasma contamination is that most cytokine-producing cell lines are not only 20 contaminated with mycoplasmas, but are also induced by the mycoplasmas. Thus, mycoplasma contamination in cell cultures may lead to unreliable experiments and mycoplasma contaminated biological products.

Therefore, it is important to test for mycoplasma contamination of cell 25 cultures. It is also useful to identify the species of mycoplasma contaminants, as an indication of possible sources of the mycoplasma. To date, several techniques have been used to detect mycoplasma contamination of cell cultures. These include culture procedures on agar, broth, or semi-solid agar-broth medium; propagation on susceptible indicator cell lines for detection of mycoplasma species that are not cultivable in cell-free medium; DNA-staining procedures with

dyes like DAPI (4',6-diamine 2'-phenylindole dihydrochloride) or H 33258 (bisbenzimide); biochemical identification methods that detect enzyme activities present in mycoplasmas but absent or minimal in non-infected cell cultures; DNA-hybridization procedures, mostly based on mycoplasmal ribosomal RNA genes; detection by specific fluorescein- or peroxidase-conjugated polyclonal antisera or monoclonal antibodies with fluorescence microscopy, enzyme-linked immunosorbent assays (ELISA, as in the Boehringer Mannheim Mycoplasma Detection Kit); and use of the polymerase chain reaction (PCR), which recently has been applied for the detection of mycoplasmas in cell cultures (Rawadi, et. al. at 199-206). The polymerase chain reaction has proven more successful as compared to earlier methods which lack combined sensitivity, specificity and speed.

The PCR process for amplifying and detecting nucleic acid sequences is described in U.S. Patents 4,683,202; 4,683,195; and 4,965,188, which are hereby incorporated by reference. The basic purpose of PCR is to amplify DNA. The PCR process consists of the following three steps which are repeated in cyclic fashion so that the primer extension products of each cycle become the templates for replication in subsequent cycles: 1) denaturation of the template at elevated temperature; 2) annealing at hybridization temperature of oligonucleotide primers to the single-stranded template DNA; and 3) extension by a thermostable DNA polymerase in the presence of nucleotide triphosphates of the 3' ends of the primers in order to replicate the desired template sequence. Repetition of this process results in the formation of DNA strands that correspond in sequence to the region between the originally used primers. Specific PCR primer pairs are used to identify particular mycoplasma species.

PCT WO 92/07095 discloses use of an arbitrarily primed polymerase chain reaction AP-PCR), in order to detect bacterial species and strains, including *Staphylococcus* and *Streptococcus* species. The process involves use of arbitrary primers used at low stringency hybridization conditions in order to generate

specific discrete products that can be resolved into a small number of individual bands providing a species "fingerprint." Specifically, the method consists of the following steps: 1) priming target nucleic acid of a genome with a single-stranded primer to form primed nucleic acid such that a substantial degree of 5 complementary base pair matching occurs between the primer and the target nucleic acid; 2) amplifying the primed nucleic acid by performing at least one cycle of PCR amplification; and 3) amplifying the product of step (2) by performing at least about 10 cycles of PCR amplification.

10 However, there are limitations to the use of PCR alone in mycoplasma testing. For example, enhanced sensitivity and/or specificity is desirable.

Nested PCR has been shown to increase the sensitivity of the mycoplasma test by at least two orders of magnitude while minimizing background from non-target DNA amplification. [Garson et al., Lancet, p. 335, 1419 (1990); Proter-Jordan, et al., J. Med. Virol., p. 30, 85 (1990); Harasawa et al., "Rapid 15 Diagnosis of Mycoplasmas," (Kahane I. and Adoni A. eds.) p. 227-231 (1993)].

The process of nested PCR refers to a two stage PCR reaction in which in the first stage 1) a pair of outer primers which flank a particular DNA segment are used to amplify that first DNA segment in stage 1, followed by a second stage 2) in which a second set of inner primers is used to amplify a smaller "target" 20 segment of nucleic acid which is contained within the first DNA segment. The nested PCR is currently the most sensitive means for detecting mycoplasma in cell cultures for the reason that a single copy of the target DNA can be detected.

U.S. Patent 5,340,728 relates to a kinetically controlled nested PCR 25 amplification method used to assay for microbial contaminants in food. The basic concept involves controlling the concentrations of the outer and inner nested primers and annealing times in the first and second stages, which results in highly specific and efficient amplification of a targeted piece of DNA. For effective nested PCR amplification, the amplification of the outer primer set must be terminated after the first stage to allow the inner primers to amplify the DNA in

the second stage.

Mattsson et al, "Oligonucleotide Probes Complementary to 16S rRNA for Rapid Detection of Mycoplasma Contamination in Cell Cultures," FEMS Microbiology Letters 107, 139-144 (1993), disclose a method for detecting 5 mycoplasma contamination using three different oligonucleotide probes complementary to 16S rRNA. Two of the probes were designed to be group-specific and one to be species-specific. Although the assay is rapid, allowing the possibility to perform and evaluate the mycoplasma testing within one working day, the method is not very sensitive.

10 Harasawa et al., "Detection and Tentative Identification of Dominant Mycoplasma Species in Cell Cultures by Restriction Analysis of the 16S-23S rRNA Intergenic Spacer Regions," Res. Microbial. 144, 489-493 (1993), teaches use of mixed sequence primers [5'(ACACCATGGGAG(C/T)TGGTAAT)3' (F1) (SEQ ID NO's:1-2)], [5'(CTCCTAGTGCCAAG(C/G)CAT(C/T)C)3' (R1) (SEQ 15 ID NO's:3-6)] for use as first stage primers, and [5'(GTG(C/G)GG(A/C)TGGATCACCTCCT)3' (F2) (SEQ ID NO's:7-10)] and [5'(GCATCCACCA(A/T)A(A/T)AC(C/T)CTT)3' (R2) (SEQ ID NO's:11-18)] for use as second stage primers. In addition, Harasawa [Harasawa, R. in Molecular and Diagnostic Procedures in Mycoplasmology (Razin, S. and J.E. 20 Tully, eds.) Vol. II A4 (i.v.) Academic Press, in press (1995)] teaches use of the mixed sequence primer [5'(CTTC(A/T)TCGACTT(C/T)CAGACCCAAGGCAT)3' (SEQ ID NO's:19- 22)] in place of [5'(CTCCTAGTGCCAAG(C/G)CAT(C/T)C)3' (SEQ ID NO's:3-6)]. However, a relatively large amount of *A. laidlawii*, (i.e., about 25 10<sup>3</sup>-10<sup>4</sup> CFU/ml) must be present in the sample in order for the test to accurately detect this mycoplasma species. Further, there is a likelihood of cross-reactivity occurring when human cell DNA is tested using the Harasawa method.

It is a requirement that researchers perform routine assays for possible contamination of all cell cultures. However, current mycoplasma testing methods

are not highly sensitive and specific. *Mycoplasma fermentans*, *M. hyorhinis* (porcine origin), *M. orale* (human origin), *M. arginini*, and *Acholeplasma laidlawii* (bovine origin), account for more than 95 % of the mycoplasma contamination in cell cultures [McGarrity et al., "Mycoplasmas and Tissue Culture Cells" in Mycoplasmas Molecular Biology and Pathogenesis. (ed. J. Maniloff, et al.) pp. 445-454 American Society for Microbiology, Washington, D.C. (1992)]. *M. pirum*, *M. hominis*, and *M. salivarium* are also common contaminants of cell culture. However, most known mycoplasma test kits do not detect all eight *Mycoplasma* species.

10 Further, most detection systems are not sensitive and specific enough to detect and identify *A. laidlawii*, because the primers are designed for detection of *Mycoplasma*. Since *Mycoplasma* and *Acholeplasma* are two different genera, the primers that detect *Mycoplasma* may not necessarily detect *Acholeplasma*. Therefore, most mycoplasma detection systems detect either *Acholeplasma* or *Mycoplasma*, but not both.

15 There exists a need for a single highly specific, highly sensitive, and rapid system for detecting and identifying a variety of known mycoplasma species and MLO, including *A. laidlawii*.

#### SUMMARY OF THE INVENTION

20 The present invention provides a highly specific, highly sensitive, rapid system for detecting and identifying a variety of known mycoplasma species and MLO, including *A. laidlawii*, *M. fermentans*, *M. hyorhinis*, *M. orale*, *M. arginini*, *M. pirum*, *M. hominis*, and *M. salivarium*. The system involves use of nested PCR, a two-stage amplification method, to produce different sized DNA amplicons depending upon the *Mycoplasma* or *Acholeplasma* species. The invention is characterized in that mixtures of single sequence and mixed sequence oligonucleotides are used as the "outer" and "inner" primers. The combination of nested PCR, along with a mixture of single sequence and mixed sequence

oligonucleotide primers complementary to the DNA sequence of the aforementioned Mycoplasmas and *A. laidlawii*, provides enhanced specificity and sensitivity.

The present invention includes a method for amplifying a target segment of nucleic acid in a nucleic acid mixture by performing a nested polymerase chain reaction to selectively amplify a target segment of nucleic acid from said sample nucleic acid reaction mixture, wherein said method comprises the steps of: a) adding a first stage primer mixture to a sample nucleic acid reaction mixture, wherein said first stage primer mixture contains a mixture of at least one single sequence and at least one mixed sequence oligonucleotide primers, in order to amplify a nucleic acid segment flanked by said outer primer pair; b) repetitively performing the polymerase chain reaction; c) adding a second stage primer mixture to said nucleic acid reaction mixture, wherein said second stage primer mixture contains a mixture of at least one single sequence and at least one mixed sequence oligonucleotide primers, in order to selectively amplify a target nucleic acid segment flanked by said inner primers; and d) repetitively performing the polymerase chain reaction.

The present invention further comprises a mycoplasma test kit for detection of the presence of a selectively amplified target segment of a nucleic acid in a nucleic acid mixture, comprising: a) a first stage primer mixture as described above; b) a second stage primer mixture as described above; c) a first positive control nucleic acid 1; and d) a second positive control nucleic acid 2.

#### BRIEF DESCRIPTION OF THE DRAWINGS

The foregoing and other objects, aspects and advantages will be better understood from the following detailed description of a preferred embodiment of the invention with reference to the drawings, in which:

Figure 1 is a strategy for two-step PCR.

Figure 2 is an agarose gel showing the relative sizes of the amplicon bands

produced following amplification of *Mycoplasma* and *Acholeplasma* DNA.

Figure 3 is an agarose gel showing the relative sizes of amplicon bands produced following amplification of *A. laidlawii* DNA using Harasawa primers and primers of the present invention.

5

## DETAILED DESCRIPTION OF A PREFERRED EMBODIMENT OF THE INVENTION

Mixed sequence primers are used in PCR reactions to obtain consistent amplification of similar target DNA sequences, for example, those from closely related microorganisms. When it is desired to extend the breadth of detection of 10 the PCR amplification, without losing the detection of the closely related microorganisms, single sequence primers can be combined with the mixed sequence primers to accomplish this objective.

Applications of this concept include simultaneous PCR testing for multiple, specific infectious agents, each of which can cause the observed, or 15 similar symptoms. In a preferred embodiment, this concept is applied to consistent and sensitive detection of the members of a group of infectious agent (class *Mollicutes*) that can cause "mycoplasma contamination" of cell cultures.

As is evident to those skilled in the art, oligonucleotide primers of defined sequence, including "mixed sequence" primers, can be prepared by chemical 20 synthesis, now performed by several commercial organizations. These chemical syntheses are well known to one of ordinary skill in the relevant art.

The present invention uses two distinguishable types of oligonucleotide primers. Primers such as [5'(ACACCATGGGAG(C/T)TGGTAAT)3' (SEQ ID NO's:1-2)] are chemically synthesized using equal molar amounts of C and T at 25 position 13, are assumed to contain equal molar amounts of the oligonucleotides 5'(ACACCATGGGAGCTGGTAAT)3' (SEQ ID NO:1) and 5'(ACACCATGGGAGTTGGTAAT)3' (SEQ ID NO:2), and are designated "mixed sequence" primers. Primers such as

[5'(AAAGTGGGCAATACCCAACGC)3' (SEQ ID NO: 23)]

are designated "single sequence" primers.

The first stage primer mixture and the second stage primer mixture comprise multiple oligonucleotide primers, wherein these primers comprise at least one single sequence primer and at least one mixed sequence primer. Preferably, at least one of the primers is specifically complementary to *A. laidlawii* DNA, in order to amplify a *Mycoplasma*- and/or *Acholeplasma*-specific nucleic acid segment.

Specific "mixed sequence" primers and "single sequence" primers can be combined to yield the "first stage primer mixture" and "second stage primer mixture." Examples of preferred primers useful in the present invention are summarized in Table 1.

TABLE 1. Example of oligonucleotide primer mixtures suitable for use in the mycoplasma detection kit.

15	First Stage Primer Mixture	
	Primer Sequence (All sequences written 5' to 3')	Primer Sequence Name(s)
	ACACCATGGGAG(C/T)TGGTAAT, SEQ ID NO's: 1-2	F1, MCGpF11
20	CTTC (A/T) TCGACTT (C/T) CAGACCCAAGGCAT, SEQ ID NO's: 19-22	R1
	AAAGTGGGCAATACCCAACGC, SEQ ID NO: 23	M78
25	TCACGCTTAGATGCTTCAGCG, SEQ ID NO: 24	M89
Second Stage Primer Mixture		
	Primer Sequence (All sequences written 5' to 3')	Primer Sequence Name(s)
30	GTG(C/G)GG(A/C)TGGATCACCTCCT, SEQ ID NO's: 7-10	R16-2, F2

GCATCCACCA(A/T)A(A/T)AC(C/T)CTT, SEQ ID NO's: 11-18	MCGpR21, R2
CCACTGTGTGCCCTTGTCCT, SEQ ID NO: 25	M34

5        Of the outer primers listed above, F1 [i.e.,  
 5'(ACACCATGGGAG(C/T)TGGTAAT)3' (SEQ ID NO's:1-2)] is present in the  
 form of an equal molar amount of 5'(ACACCATGGGAGCTGGTAAT)3'  
 (SEQ ID NO:1), and 5'(ACACCATGGGAGTTGGTAAT)3' (SEQ ID NO:2).  
 Similarly, R1 [i.e., 5'(CTTC(A/T)TCGACTT(C/T)CAGACCCAAGGCAT)3'  
 (SEQ ID NO's:19-22)] is present in equal molar amounts of  
 5'(CTTCATCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:19),  
 5'(CTTCATCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:21),  
 5'(CTTCTTCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:20), and  
 5'(CTTCTTCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:22).

10      15     Of the inner primers listed above, F2 [i.e.,  
 5'(GTG(C/G)GG(A/C)TGGATCACCTCCT)3' (SEQ ID NO's:7-10)] is present  
 in equal molar amounts of 5'(GTGCGGATGGATCACCTCCT)3' (SEQ ID  
 NO:7), 5'(GTGGGGCTGGATCACCTCCT)3' (SEQ ID NO:10),  
 5'(GTGCGGCTGGATCACCTCCT)3' (SEQ ID NO:9) and  
 5'(GTGGGGATGGATCACCTCCT)3' (SEQ ID NO:8). Similarly, R2, [i.e.,  
 5'(GCATCCACCA(A/T)A(A/T)AC(C/T)CTT)3' (SEQ ID NO's:11-18)] is  
 present in equal molar amounts of 5'(GCATCCACCAAAAAACCCTT)3' (SEQ ID  
 NO:11), 5'(GCATCCACCAAAACTCTT)3' (SEQ ID NO:15),  
 5'(GCATCCACCAAAATACCCTT)3' (SEQ ID NO:13),  
 20      25     5'(GCATCCACCAAAACTCTT)3' (SEQ ID NO:16),  
 5'(GCATCCACCAATAACCCTT)3' (SEQ ID NO:12),  
 5'(GCATCCACCAAAACTCTT)3' (SEQ ID NO:17),  
 5'(GCATCCACCATATAACCCTT)3' (SEQ ID NO:14), and  
 5'(GCATCCACCATATAACTCTT)3' (SEQ ID NO:18).

The outer and inner primers can be present in an amount of from 10-40 pmol/ $\mu$ l preferably 20 pmol/ $\mu$ l.

Although the above listed primers comprise the preferred method of the invention, the invention is not intended to be limited to these primers and can be 5 used with any suitable primer set, comprising at least one single sequence and at least one mixed sequence primer.

The present invention involves use of a "nested" PCR reaction, which refers to a two-stage amplification reaction in which in stage 1) a segment of nucleic acid is amplified using a first stage primer mixture comprised of both 10 mixed sequence primers and single sequence primers, followed by a second stage 2) in which a second stage primer mixture comprised of both mixed sequence primers and single sequence primers is used to further amplify a smaller segment of target nucleic acid. Both first- and second-stage primers will flank the target 15 nucleic acid. As a result, the final amplified product is obtained within the frame of the first segment of nucleic acid.

Prior to addition of the primer mixtures, nucleic acid can be extracted and precipitated. This is usually not necessary in PCR assays for detection of mycoplasmas in fresh cell cultures or in fetal calf serum. However, it is recommended that nucleic acid be extracted from test samples which may contain 20 inhibitors of PCR, i.e., samples directly taken from frozen cell cultures or from reconstituted, lyophilized virus stocks and other biological material.

The present method includes partial purification of nucleic acid from the test samples which can be done by a number of means. (Refer to: "THE POLYMERASE CHAIN REACTION" (MULLIS, K.B., FERRE, F., and 25 GIBBS, R.A. eds.)(1994) Birkhauser Boston, p.4849). For example, the mycoplasma cells can be concentrated followed by cell-lysis, then the released nucleic acid is precipitated and further dissolved for PCR.

After the sample is prepared, the first-stage primer mixture and other necessary reagents are added and followed by the PCR. An aliquot of the

resulting reaction mixture is then added to the second-stage reaction mixture with second-stage primer mixture and again subjected to the PCR. The PCR reaction and nested PCR method are both disclosed in U.S. Patent 4,683,202, which is hereby incorporated by reference. Although the present invention uses two stages 5 of amplification, the present invention can be modified to use more than two stages of amplification. Specifically, three or even more stages of amplification can be employed, especially if additional selectivity in the amplification of target nucleic acid is desired.

10 An outline of the strategy for the two-step PCR as used in the present invention is shown in Figure 1.

PCR can be carried out in any authorized thermal cycler, particularly according to instructions in a Perkin-Elmer Model 2400 thermal cycler. A preferred temperature profile for this PCR reaction is first to denature the nucleic acid at 94°C for 30 seconds, then perform 30 cycles each of which consists of 15 denaturation at 94°C for 30 seconds, annealing primers at 55°C for 2 minutes, and extension at 72°C for 2 minutes. Afterwards, it is preferred that the cycler be heated an additional 5 minutes at 72°C. Optimization of the denaturation hybridization-synthesis conditions for alternative oligonucleotides is well within the skill in the art.

20 The present invention uses PCR to amplify the spacer region between 16S and 23S rRNA genes of mycoplasmas. Preferred primer sequences useful in the present invention are derived from conserved regions of *Mycoplasma* rRNA operons. In general, any suitable primer which is complementary to the conserved DNA region of a *Mycoplasma* species can be used in the present invention. 25 However, the present invention is not intended to be limited to these primers.

Specifically referring to the hard to detect species, *A. laidlawii*, this species has at least two rRNA operons, each having different sequences in the spacer region. In a preferred embodiment of the invention, the *A. laidlawii*-specific primers M78, M89 and M34 are used in order to consistently

produce a two-banded PCR product from *A. laidlawii* genomic DNA. This is in contrast to other mycoplasma test kits which do not consistently produce a two banded PCR product for the detection of *A. laidlawii*.

Identification of *Mycoplasma* and *Acholeplasma* contaminants can be done 5 using size identification techniques or using known restriction enzyme digest mapping in order to identify the specific mycoplasma species present in a sample. For example, the size of each second stage PCR amplicon can be estimated by resolving the product in 3-4% Nusieve 3:1 agarose (FMC), 1.2% agarose (Gibco BRL), 2 to 3% metaphor agarose (FMC), or using 5% polyacrylamide gel 10 followed by ethidium bromide staining. Any matrix that is suitable for distinguishing nucleic acids of the size of the expected PCR products can be used.

Also, restriction enzyme digestion can be used for identification of diagnostic fragments. For example, restriction endonucleases (VspI, ClaI, HindIII, HaeIII) can be used to digest the second stage products from the 15 commonly encountered mycoplasma. Digested PCR products can be resolved by electrophoresis on 5% polyacrylamide gel or 2-3% metaphor agarose (FMC) with ethidium bromide staining.

Usually, the second stage PCR product is used for determination. It is recommended to use 1.2% agarose (BRL) for the resolution of the amplified 20 DNA products.

Using primer mixtures in the present invention, *Mycoplasma* contaminants should generate a one-banded product in the range of 236-365 bp. In addition, *A. laidlawii* should consistently produce a double-banded product. Positive and negative controls should be included to ensure that the PCR conditions are correct 25 and the reaction is working. Suitable positive controls for a mycoplasma assay are, for example, *M. pirum* DNA and *A. laidlawii* DNA. *M. pirum* DNA control template should produce a single band of 323 bp. A double banded product (426 bp and 219 bp, respectively) would be seen for *A. laidlawii* after the second run PCR. The negative control can be distilled water in the place of the template. No

discrete band should be seen after the second stage PCR in this case.

Any other suitable identification technique can be used to identify the amplified nucleic acid resulting from the present method. For example, suitable identification techniques include digestion with specific restriction enzymes, and 5 nucleic acid hybridization with *Mycoplasma* species-specific probes.

The present invention further includes a mycoplasma test kit for detection of the presence of a selectively amplified target segment of a nucleic acid in a nucleic acid mixture. The kit comprises: 1) a first stage primer mixture containing a mixture of at least one single sequence and at least one mixed sequence 10 oligonucleotide primers; 2) a second stage primer mixture, wherein said second stage primer mixture contains a mixture of at least one single sequence and at least one mixed sequence oligonucleotide primers; 3) a first positive control nucleic acid 1; and 4) a second positive control nucleic acid 2. For example, the preferred primers and amounts listed above apply to the kit as well. Moreover, 15 the reagents can be provided in a more concentrated form for dilution to the appropriate concentration, and amounts by the end user.

Also present in the kit are one or more positive nucleic acid controls as listed above. Other *Mycoplasma* genomic DNA can be used as the positive controls. For example, genomic DNA of ATCC 17981, *M. hyorhinis*; ATCC 20 19989, *M. fermentans*; ATCC 23064, *M. salivarium*; ATCC 23114, *M. hominis*; ATCC 23714, *M. orale*; and ATCC 23838, *M. arginini* can be included in the kit.

The positive control nucleic acids can be present in the kit in an amount of from 5ng to 50ng, preferably 10ng in 50 $\mu$ l of solution, preferably sterile, distilled 25 water. Other suitable buffers that do not inhibit the PCR reaction can be used. The first stage and second stage primer mixtures are present in the kit in an amount of 0.5 to 5nmoles, preferably 1nmole in 50 $\mu$ l of solution, preferably sterile, distilled water. The first stage and second stage primer mixtures of the kit can be provided in an amount to enable a plurality of tests, such as, for at least 50

reactions. Similarly, the two positive controls of the kit can be used for at least 10 reactions. It is desirable for a kit of the present invention to be stored at -20°C. In the case of the exemplified mycoplasma kit, components of the kit are stable upon freezing and thawing for up to 12 times.

5 The kit of the present invention can comprise a plurality of vessels housing the components of the kit. For example, one or more separate vessels can contain a first stage primer set, a second stage primer set, a first positive control and a second positive control, all of which have been previously identified.

10 Preferably the kit of the present invention will comprise a plurality of vessels, wherein a first vessel contains a mixture of first stage primers comprising at least one single sequence and at least one mixed sequence oligonucleotide; a second vessel containing a mixture of second stage primers, wherein said second stage primer mixture comprises at least one single sequence oligonucleotide and a least one mixed sequence oligonucleotide; a third vessel containing a first positive 15 control nucleic acid; and a fourth vessel containing a second positive control nucleic acid.

The vessels can be of any size suitable for housing the above components and suitable for safe and secure transport. The size of the vessels will depend on the amount of solution desired. For example, the vessels can be cylindrical, 20 tubular, cubical, rectangular, or the like. Although any suitable material can be used for the composition of the vessels, it is preferred that the vessels are plastic or glass-like test tubes. The tubes can be packaged in any container capable of storing and transporting one or more vessels.

25 The present invention is useful for amplifying nucleic acids from environmental samples or research samples of cell cultures, viral stocks, and biopharmaceutical reagents. In addition, the present invention can be used for diagnosis of mycoplasma, including MLO, infection in plants, insects, animals and in clinical isolates. Moreover, the present invention can be used for diagnostic or forensic purposes. Typical examples of these types of biological

sources includes human or animal samples containing blood, urine, tissue, semen, bacteria and hair.

The method and kit of the present invention can be used for both detection of the presence of mycoplasma and for identification of the specific mycoplasma contained in the reaction sample. By "sample nucleic acid mixture", applicants refer to a sample containing nucleic acids and mixtures thereof from any strain, species, class or genera of organisms. Specifically, a preferred embodiment of the method and kit of the present invention are applicable to amplifying a segment of DNA of the genome in class *Mollicutes*. Other specific examples include a 5 microorganism selected from the group consisting of *Acholeplasma laidlawii*, *A. modicum*, *A. morum*, *Mycoplasma fermentans*, *M. hyorhinis*, *M. orale*, *M. hominis*, *M. arginini*, *M. pirum*, *M. salivarium*, *M. hyopneumoniae*, *M. neurolyticum*, *M. pulmonis*, *M. pneumoniae*, *M. capricolum*, *M. arthritidis*, *M. gallinarum*, *M. hyosynoviae*, *M. mycoides*, *M. bovis*, *Entomoplasma ellychniae*, 10 *Em. lucivorax*, *Em. melaleucae*, *Em. somnilux*, *Mesoplasma entomophilum*, *Ms. pleciae*, *Ms. photuris*, *Ms. chauliocola*, *Ms. corruscae*, *Ms. grammopterae*, *Ms. coleopterae*, *Ms. tabanidae*, *Ms. lactucae*, *Ms. seiffertii*, *Ms. florum*, *Ureaplasma urealyticum*, *U. gallorale*, *U. canigenitalium*, *U. diversum*, *Spiroplasma chinense*, *Sp. citri*, *Sp. florcola*, *Sp. kunkelii*, *Lactobacillus casei*, and 15 *Lactobacillus rhamnosus*. No mycoplasma- specific amplicon bands were observed upon testing the following microorganisms: *Bacillus subtilis*, *L. catenaformis*, *Clostridium ramosum*, *C. innocuum*, *Escherichia coli*, *Enterococcus faecalis*, human DNA including ATCC CRL 1611, CCL 119, CCL 86, CCL 187, mouse DNA including ATCC HB 72, HB 96, HB 144, HB 167, 20 HB 194, CRL 1581, rat DNA ATCC HB 219 and HB 221, hamster DNA HB 226 and HB 218, and monkey DNA ATCC CRL 1587, CCL 81. Therefore, the exemplified embodiment of the present invention is specific to mycoplasma 25 organisms containing no cell wall, showing no cross-reactivity with many related bacteria (except for *Lactobacillus*), as well as mammalian cells.

The exemplified embodiment of the present invention is highly sensitive, possessing the ability to detect at least 0.1 to 1.6 colony-forming units (CFU) of *Mycoplasma/Acholeplasma* per sample (5 $\mu$ l). The sensitivity for detecting *A. laidlawii* is as high as 0.1 CFU per 5 $\mu$ l sample. This high sensitivity is 5 particularly valuable when screening cell cultures contaminated with a low amount of mycoplasma, detecting those fastidious species of mycoplasma that hardly grow by the direct culture method, and in monitoring removal of mycoplasma contaminants from cell cultures by drug treatment.

The exemplified embodiment of the present invention also has a broad 10 detection range, detecting a wide variety of *Mycoplasma* and *Acholeplasma* species and MLO's. The primer mixtures of the exemplified embodiment of the method and kit can universally detect all *Mycoplasma* and *Acholeplasma* species commonly encountered in cell cultures. The exemplified embodiment of the present invention also allows for rapid and easy use. The entire nested PCR assay 15 can be completed within one working day. In addition, the results of the PCR assay are easy to read.

The instant invention now will be exemplified in the following 20 non-limiting examples. Other embodiments of the present invention are not exemplified herein. However, it is not intended that applicants be limited to the scope of the specific embodiments set forth herein

#### EXAMPLE I

##### **Extraction of DNA**

DNA was extracted from test samples (listed in Table 6 below) possibly 25 contaminated with mycoplasma and containing PCR inhibitors (i.e. samples directly taken from the frozen cell cultures or from reconstituted, lyophilized virus stocks).

An amount of 500 $\mu$ l of cell suspension or reconstituted biological was transferred to a sterile microcentrifuge tube. The cells were collected by centrifugation at 12,000g for 20 minutes in an Eppendorf microcentrifuge. The

cell pellet was resuspended in 100 $\mu$ l of lysis buffer (1x PCR buffer, 0.5% NP-40, 0.5% Tween 20). An amount of 1 $\mu$ l proteinase K (17.3 mg/ml) was added to the suspension. The resulting suspension was incubated at 60°C for one hour.

The enzyme was inactivated by heating at 95°C for 10 minutes. An 5 amount of 500  $\mu$ l of dH<sub>2</sub>O was then added to the solution. Next, 600 $\mu$ l isopropanol and 1  $\mu$ l of glycogen (20 mg/ml) were added and the solution mixed gently by inverting the tube. The resulting solution was incubated at -20°C for at least 30 minutes.

The DNA pellet was collected by centrifugation at 12,000 g for 30 10 minutes at 4°C. The supernatant was discarded and the DNA pellet washed in 500 $\mu$ l of cold 75% ethanol. Next, the pellet was centrifuged at 12,000g for 10 minutes at 4°C. The step of discarding the supernatant, washing the pellet, and centrifugation was repeated once again.

All the supernatant again was carefully discarded. The DNA pellet was 15 allowed to dry. Next, the DNA was resuspended in 50 $\mu$ l dH<sub>2</sub>O and kept at 4°C, or -20°C until ready for the nested PCR.

#### First Stage PCR

DNA was prepared as outlined above. In a 200  $\mu$ l or a 500  $\mu$ l tube, 36.8 20  $\mu$ l sterile distilled water was mixed with 5  $\mu$ l of 10x PCR buffer (100 mM Tris-HCl, pH 8.3; 500mM HCl; 15mM MgCl<sub>2</sub>; and 0.01% w/v gelatin), 1 $\mu$ l of dNTP's (2.5mM each), 1 $\mu$ l of 25mM MgCl<sub>2</sub>, 0.2 $\mu$ l of 5 units/ $\mu$ l of Taq DNA polymerase. Next, 1 $\mu$ l (20 pmole/ $\mu$ l each) of the "first stage primer mixture" was added. The first stage primer mixture sequences were as follows:

25 "Mixed sequence" 5'(ACACCATGGGAGCTGGTAAT)3' (SEQ ID NO:1)  
primer F1 5'(ACACCATGGGAGTTGGTAAT)3' (SEQ ID NO:2)  
"Mixed sequence" 5'(CTTCATCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:19)  
primer R1 5'(CTTCTTCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:20)  
5'(CTTCATCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:21)

5'(CTTCTTCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:22)

"Single sequence" 5'(AAAGTGGGCAATACCCAACGC)3' (SEQ ID NO:23)  
primer M78

"Single sequence" 5'(TCACGCTTAGATGCTTCAGCG)3' (SEQ ID NO:24)  
primer M89

5 In a preferred embodiment, the relative molar ratios of the individual oligonucleotide components of F1, R1, M78 and M89 were 0.5:0.25:1:1, respectively. It will be evident to those skilled in the art that other molar ratios of the oligonucleotide primers, particularly ratios that increase the relative amount of the primers present in lowest concentration, may be advantageous.

10 Finally, 5 $\mu$ l of the template DNA was added. The total reaction volume was 50 $\mu$ l.

It is possible to make the reaction mixture in one stock and aliquot 45 $\mu$ l of the mixture to each 200 $\mu$ l or 500 $\mu$ l tube, and then add 5 $\mu$ l of template DNA or cell culture fluid.

15 For each PCR run, two positive DNA controls and one negative control should be included. For the positive control, 5 $\mu$ l (1ng) of *M. pirum* DNA and 5 $\mu$ l (1ng) of *A. laidlawii* DNA were pipetted into two separate tubes. For the negative control, 5 $\mu$ l of sterile distilled water was pipetted into one tube.

20 The PCR reaction was carried out in a Perkin-Elmer thermal cycler for 30 cycles in order to amplify the DNA. The thermal cycler was first heated to 94°C for 30 seconds, and then performed 30 cycles each consisting of 94°C for another 30 seconds, 55°C for 2 minutes, and 72°C for 2 minutes. After the last of the 30 cycles, an additional 5 minutes at 72°C was added.

### Second Stage PCR

25 For the second stage reaction, in a 200 $\mu$ l or a 500 $\mu$ l tube, 40.8 $\mu$ l of sterile distilled water was mixed with 5 $\mu$ l of 10x PCR buffer (same as in the first stage PCR), 1 $\mu$ l of dNTP's (2.5mM each as in the first stage PCR), 1 $\mu$ l of 25mM MgCl<sub>2</sub>, 0.2 $\mu$ l of 5units/ $\mu$ l of Taq DNA polymerase. Next, 1 $\mu$ l (20 pmole/ $\mu$ l) of

"second stage primer mixture" was added. The second stage primer mixture sequences were as follows:

5 "Mixed sequence" 5'(GTGGGGCTGGATCACCTCCT)3' (SEQ ID NO:10)  
primer F2 5'(GTGGGGATGGATCACCTCCT)3' (SEQ ID NO:8)  
5'(GTGCGGATGGATCACCTCCT)3' (SEQ ID NO:7)  
5'(GTGCGGCTGGATCACCTCCT)3' (SEQ ID NO:9)

5 "Mixed sequence" 5'(GCATCCACCAAAACCCCTT)3' (SEQ ID NO:11)  
primer R2 5'(GCATCCACCATAAACCCCTT)3' (SEQ ID NO:12)  
5'(GCATCCACCAAATACCCCTT)3' (SEQ ID NO:13)  
5'(GCATCCACCATATAACCCCTT)3' (SEQ ID NO:14)  
5'(GCATCCACCAAAACTCT-1)3' (SEQ ID NO:15)  
5'(GCATCCACCATAAACTCTT)3' (SEQ ID NO:17)  
5'(GCATCCACCAAATACTCTT)3' (SEQ ID NO:16)  
5'(GCATCCACCATATACTCTT)3' (SEQ ID NO:18)

"Single sequence" 5'(CCACTGTGTGCCCTTGTTCCCT)3' (SEQ ID NO:25)  
primer M34

In a preferred embodiment, the relative molar ratios of individual oligonucleotide components of F2, R2, and M34 were 0.25:0.125:1, respectively. It will be evident to those skilled in the art that other molar ratios of the oligonucleotide primers, particularly ratios that increase the relative amount of the primers present in lowest concentration, may be advantageous.

Finally, 1 $\mu$ l of template DNA from the first stage PCR product was added. The total reaction volume was 50 $\mu$ l. The PCR reaction was carried out in the Perkin-Elmer thermal cycler for 30 cycles as in the first stage PCR.

Nested PCR is an extremely sensitive method for amplification of DNA. An amount of 10<sup>12</sup> DNA copies can be generated from one template sequence.

Depending on the type of thermal cycler used, it may be necessary to overlay each tube with 2 drops of mineral oil (40-60 $\mu$ l) to prevent formation of

condensation. In this case it is recommended to overlay mineral oil before adding the samples into the tubes as set forth, above.

#### Interpretation and analysis of PCR results

PCR products are analyzed by using standard gel electrophoresis. An 5 amount of 10  $\mu$ l of amplified DNA from the second stage PCR was run on 1.0 to 1.4 % agarose or 2-3% metaphor agarose.

Identification can be done using size identification method or using known 10 restriction digest mapping in order to identify the specific mycoplasma species present in a sample. For example, the size of each second stage PCR amplicon agarose, 2-3% metaphor agarose gel, or using 5% polyacrylamide gel electrophoresis followed by ethidium bromide staining and observation. The migration pattern of the amplicons from the eight commonly encountered mycoplasma species is shown in Figure 2.

15 In addition, restriction endonucleases (i.e., VspI, ClaI, HindIII) can be used to digest the second stage PCR products from the commonly encountered mycoplasma. The sizes of the restriction digest fragments for each Mycoplasma species are presented in Table 2.

20 Table 2. Variations of restriction fragment lengths of the 16S-23S rRNA intergenic spacer regions of commonly encountered species of mycoplasma.

Mycoplasma species	Second stage PCR product	Restriction Fragments		
		Vsp I	Hind III	Cla I
<i>M. arginini</i>	236 bp	134, 102	-*	-
<i>M. fermentans</i>	365	270, 95	241, 124	-
<i>M. hominis</i>	236**	123, 113	-	-
<i>M. hyorhinis</i>	315	-	-	253, 62
<i>M. orale</i>	290	151, 139	-	-
<i>M. pirum</i>	323	169, 154	285, 38	-

<i>M. salivarium</i>	269	-	-	-
<i>A. laidlawii</i>	426, 219	219, 198, 189, 39	-	-

\* “-” means no restriction site observed.  
 \*\* When polyacrylamide gel is used for the resolution of amplified DNA products, a double band product with one base pair difference may be observed for *M. hominis*. This feature can serve as a good indicator for differentiating *M. hominis* from *M. arginini*, which only produces a single band DNA product.

The above results demonstrate that the present invention detects seven commonly encountered Mycoplasma contaminants of cell cultures plus *A. laidlawii*.

EXAMPLE 2

In order to determine the sensitivity of the present detection system the following experiment was performed. Serial dilution of actively growing *Mycoplasma* and *Acholeplasma* cultures was done, and the diluted aliquots were plated on appropriate media to obtain 30-300 colonies per plate. The diluted aliquots were then subjected directly to nested PCR amplification as outlined above. After the colony counts were obtained, the total number of colony forming units (CFU) present in the diluted aliquots subjected to nested PCR amplification was calculated. The total CFU counts were correlated with the PCR results, and the sensitivity of detection was determined. The results of the sensitivity testing are shown in Table 3.

Table 3. Sensitivity testing of Example 1 species

NAME	ATCC#	SENSITIVITY
<i>A. laidlawii</i>	23206	20 CFU/ml (0.1 cell/5 $\mu$ l)
<i>M. fermentans</i>	19989	100 CFU/ml (0.5 cell/5 $\mu$ l)
<i>M. pirum</i>	25960	100 CFU/ml (0.5 cell/5 $\mu$ l)
<i>M. hyorhinis</i>	17981	100 CFU/ml (0.5 cell/5 $\mu$ l)
<i>M. orale</i>	23714	320 CFU/ml (1.6 cell/5 $\mu$ l)

<i>M. hominis</i>	23114	100 CFU/ml (0.5 cell/5 $\mu$ l)
<i>M. salivarium</i>	23064	180 CFU/ml (0.9 cell/5 $\mu$ l)

The above results demonstrate the enhanced sensitivity of the present invention. Specifically, as low as 20 CFU/ml could be detected for *A. laidlawii*.

5 The sensitivity of *A. laidlawii* from other known mycoplasma detection systems is around 1000 CFU/ml (Harasawa et al. (1993) at 227-231). For other *Mycoplasma* species, the present invention can detect less than one CFU per 5 ml sample, or less than 200 CFU/ml (except for *M. orale*). Other known mycoplasma detection systems report the detection of one cell per sample, or 1000 CFU/ml.

10 **EXAMPLE 3**

To illustrate the increased sensitivity of detection of *A. laidlawii* DNA by the combination of primers shown in Table 1 compared to the oligonucleotide primers developed by Harasawa et al, the following experiment was performed. One ng of partially purified (see Example 1) *A. laidlawii* DNA, and further 15 dilutions of this solution were used as DNA template in the "nested" two stage PCR reaction. Two sets of primer mixtures were compared. One consisted of the primers recommended by Harasawa, et al., i.e. F1 and R1 for the first stage PCR reaction, and F2 and R2 for the second stage PCR reaction. The other consisted of the present first stage primer mixture and the second stage primer mixture of 20 the instant invention, which comprises single sequence primers, along with mixed sequence primers as described in Table 1 above. The primers and *A. laidlawii* DNA were combined and subjected to "nested" two stage PCR as described in Example 1. The results are summarized in Figure 3 herein.

Note that no typical two band *A. laidlawii* amplicon pattern is seen with 25 the Harasawa primers, even with a concentrated amount of 1ng of *A. laidlawii* DNA present as template in the reaction. In contrast, the primer mixtures of the instant invention are able to produce the typical two band *A. laidlawii* amplicon pattern even at a 1:1000 dilution of the 1ng of *A. laidlawii* DNA template. This

demonstrates the enhanced sensitivity of detection of *A. laidlawii* using the primer mixtures described herein, wherein a mixture of mixed sequence primers and single sequence primers are used, as compared to use of only mixed sequence primers as described by Harasawa et al.

5 **EXAMPLE 4**

The following single sequence primers were combined with only the second stage "mixed sequence" primer F2 (see Table 1) and tested for the ability to amplify DNA from a variety of sources using the second stage reaction conditions described above.

10 R32: [5'(TATATTGGTGGAGCCTAGCGG)3' (SEQ ID NO:26)]

R33: [5'(ATTGGTGGAGCCTAGCGG)3' (SEQ ID NO:27)]

M34: [5'(CCACTGTGTGCCCTTGTTCCT)3' (SEQ ID NO:25)]

The results are summarized in Table 4 below.

15 Table 4. Comparison of different possible "single sequence" *A. laidlawii* primers for only the second stage amplification reaction.

Sample	Primers F2 + R32	Primers F2 + R33	Primers F2 + M34
<i>A. laidlawii</i> (ATCC 23206)	Single band	Single band	T(Doub. band)
<i>A. laidlawii</i> (ATCC 31166)	Single band	Single band	T(Doub. band)
<i>M. arginini</i> (ATCC 23838)	0	0	0
20 <i>M. fermentans</i> (ATCC 19989)	0	0	AT
<i>M. hominis</i> (ATCC 23114)	Single band	Single band	0
<i>M. salivarium</i> (ATCC 23064)	Single band	Single band	0
25 <i>M. hyorhinis</i> (ATCC 17981)	0	0	0
<i>M. orale</i> (ATCC 23714)	0	0	0
<i>M. pirum</i> (ATCC 25960)	0	0	0

	<i>Bacillus subtilis</i> (ATCC 6051)	T	0	0
5	<i>Lactobacillus rhamnosus</i> (ATCC 7469)	AT	AT	Single band
	<i>L. casei</i> (ATCC 393)	0	AT	Single band
	<i>Enterococcus faecalis</i> (ATCC 19433)	0	0	0
	<i>Escherichia coli</i> (ATCC 11775)	0	0	0
10	<i>Clostridium ramosum</i> (ATCC 25582)	0	0	0
	<i>Clostridium innocuum</i> (ATCC 14501)	0	0	0
	<i>Lactobacillus catenaformis</i> (ATCC 25536)	0	0	0
15	<i>Clostridium pasteurianum</i> (ATCC 6013)	0	0	0
	negative control	0	0	0
20	T = typical two band ( <i>A. laidlawii</i> ) or single band ( <i>Mycoplasma</i> ) DNA amplicon band observed.			
	0 = no amplicon bands seen			
	AT = amplicon band(s) seen outside the size range of <i>Mycoplasma</i> and <i>Acholeplasma</i> amplicons.			

Note that when oligonucleotides R32 and R33 were used amplicon bands that could have confused the interpretation of results with *M. hominis*, *M. salivarium*, were observed. A similar, potentially confusing band was noted for *B. subtilis*. However, this was not the case with M34. Although M34 does show amplification with *L. rhamnosus* and *L. casei*, it was selected for further testing as being preferable to R32 or R33.

30 **EXAMPLE 5**

A first stage PCR reaction was performed using a variety of template DNAs and a first stage primer mixture containing F1, M78, R1 and M89 (see

Table 1). An aliquot of the first stage reaction product was combined with a second stage primer-mixture containing (F2, R2, and R32) or (F2, R2, and M34) and then second stage PCR amplification was carried out. The results are summarized in Table 5 below.

5 Note that when the second stage primer mixture (F2, R2, and R32) was used, a cross reaction with a variety of mammalian DNA samples and *B. subtilis* was observed. The second stage primer mixture (F2, R2, and R32) also gave an atypical one band pattern with *A. laidlawii*. M34 was again considered preferable to R32.

10 Table 5. Comparative specificity of R32 and M34 with a variety of DNA templates.

Sample	Primer mixture (F2, R2, R32)	Primer mixture (F2, R2, M34)
mouse DNA (ATCC HB 144)	AT	0
mouse DNA (ATCC HB 96)	AT	0
15 mouse DNA (ATCC HB 72)	AT	0
mouse DNA (ATCC HB 167)	AT	0
rat DNA (ATCC HB 221)	AT	0
rat DNA (ATCC HB 219)	AT	0
hamster DNA (ATCC HB 226)	AT	0
20 human DNA (ATCC CRL 1611)	0	0
human DNA (ATCC CCL 119)	0	0
human DNA (ATCC HTB 31)	0	0
human DNA (ATCC CCL 187)	0	0
25 monkey DNA (ATCC CCL 81)	AT	S
monkey DNA (ATCC CRL 1587)	AT	S
rat DNA (ATCC HB 229)	AT	S
hamster DNA (ATCC HB 218)	AT	S

mouse DNA (ATCC HB 194)	AT	S
human DNA (ATCC CCL 86)	AT	S
Bacillus subtilis (ATCC 6051)	Single band	0
Lactobacillus (L.) rhamnosus (ATCC 7469)	0	Single band
L. casei (ATCC 393)	0	Single band
M. hominis (ATCC 23114)	Single band	T
A. laidlawii (ATCC 23206)	Single band	T (Double band)
negative control	0	0

### EXAMPLE 6

A first stage PCR reaction was performed using a variety of template DNAs and the first stage primer mixture containing F1, M78, R1 and M89 (see Table 1). An aliquot of the first stage reaction product was combined with either the primer mixture (F2, R2, R32) or (F2, R2, M34) and second stage PCR amplification was carried out. The results are summarized in Table 6.

Table 6. Comparative specificity of “single sequence” primers R32 and M34 with Mycoplasma DNA templates

Sample	Primer mixture (F2, R2, R32)	Primer mixture (F2, R2, M34)
<i>Acholeplasma laidlawii</i> (ATCC 23206)	atypical one band pattern	typical two band pattern
<i>Mycoplasma fermentans</i>	T	T
<i>M. hyorhinis</i>	T	T
<i>M. pirum</i>	T	T

<i>M. hominis</i>	T	T
<i>M. arginini</i>	T	T
<i>M. orale</i>	T	T
<i>M. salivarium</i>	T	T
5 negative control	0	0

T = typical one-band (*Mycoplasma*) or two-band (*Acholeplasma*) amplicon pattern observed.  
0 = no amplicon bands observed.

10 The atypical one band pattern observed when primer R32 was used in place of M34 again favors the use of M34.

All references cited herein are incorporated herein in their entirety. It will be evident that obvious modifications and applications can be made to the teachings herein without departing from the spirit and the scope of the instant invention.

15 While the invention has been described in terms of a single preferred embodiment, those skilled in the art will recognize that the invention can be practiced with modification within the spirit and scope of the appended claims.

## CLAIMS

Having thus described our invention, what we claim as new and desire to secure by Letters Patent is as follows:

1. 1. A method for amplifying a target segment of nucleic acid in a sample nucleic acid mixture by performing a two stage polymerase chain reaction to selectively amplify a nucleic acid comprising said target segment of nucleic acid of said sample nucleic acid mixture, wherein said method comprises the steps of:
  5. adding a first stage PCR primer set for amplifying a target segment of nucleic acid to sample nucleic acid mixture to amplify nucleic acid flanked by primers in said first stage PCR primer set and containing said target segment, wherein said first stage PCR primer set comprises
    9. single sequence primers complementary to said nucleic acid including 5'(AAAGTGGGCAATACCCAACGC)3' (SEQ ID NO: 23), and
    11. 5'(TCACGCTTAGATGCTTCAGCG)3' (SEQ ID NO:24), and
    12. at least one of the first mixed sequence primer set including primers complementary to said nucleic acid selected from the group consisting of 5'(ACACCATGGGAGCTGGTAAT)3' (SEQ ID NO:1) and 5'(ACACCATGGGAGTTGGTAAT)3' (SEQ ID NO:2) and
    16. at least one of a second mixed sequence primer set including primers complementary to said nucleic acid selected from the group consisting of 5'(CTTCATCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:19), 5'(CTTCTTCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:22)
    20. 5'(CTTCATCGACTTCAGACCCAAGGCAT) 3' (SEQ ID NO:21), and 5'(CTTCTTCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:20);
  22. adding a second stage PCR primer set for amplifying said target segment of nucleic acid to said sample nucleic acid mixture to amplify nucleic acid flanked by primers in said second stage PCR primer set and containing said target

25 segment, wherein said second stage PCR primer set comprises  
26 a single sequence primer complementary to said nucleic acid having the  
27 sequence  
28 5'(CCACTGTGTGCCCTTGTCCT)3' (SEQ ID NO:25), and  
29 at least one of a first mixed sequence primer set including primers  
30 complementary to said nucleic acid selected from the group consisting of  
31 5'(GTGCGGATGGATCACCTCCT)3' (SEQ ID NO:7),  
32 5'(GTGGGGCTGGATCACCTCCT)3' (SEQ ID NO:10),  
33 5'(GTGCGGCTGGATCACCTCCT)3' (SEQ ID NO:9), and  
34 5'(GTGGGGATGGATCACCTCCT)3' (SEQ ID NO:8), and  
35 at least one of a second mixed sequence primer set including primers  
36 complementary to said nucleic acid selected from the group consisting of  
37 5'(GCATCCACCAAAACCCCTT)3' (SEQ ID NO:11),  
38 5'(GCATCCACCAAAACTCTT)3' (SEQ ID NO:15),  
39 5'(GCATCCACCAAATACCCCTT)3' (SEQ ID NO:13),  
40 5'(GCATCCACCAAATACTCTT)3' (SEQ ID NO:16),  
41 5'(GCATCCACCAATAACCCCTT)3' (SEQ ID NO:12),  
42 5'(GCATCCACCAATAACCTCTT)3' (SEQ ID NO:17),  
43 5'(GCATCCACCAATACCCCTT)3' (SEQ ID NO:14), and  
44 5'(GCATCCACCAATACCTCTT)3' (SEQ ID NO:18) and  
45 repetitively performing polymerase chain reaction after both of said adding  
46 steps.

1 2. The method of claim 1 further comprising the step of selecting the target  
2 segment of nucleic acid to be comprised of deoxyribonucleic acid.

1 3. The method of claim 2 further comprising the step of selecting the target  
2 segment of nucleic acid to be diagnostic of a selected class, genus, species or  
3 subspecies of microorganism.

- 1        4. The method of claim 3 further comprising the step of selecting the sample
- 2        nucleic acid mixture to be comprised of deoxyribonucleic acid extracted from
- 3        microorganisms of undetermined identity.
  
- 1        5. The method of claim 1 further comprising the step of detecting the presence of
- 2        the amplified target segment.
  
- 1        6. The method of claim 5 further comprising the step of identifying a particular
- 2        class, genus, species or subspecies of microorganism in the nucleic acid mixture.
  
- 1        7. The method of claim 6, wherein the particular class of microorganism is
- 2        *Mollicutes*.
  
- 1        8. The method of claim 7, wherein the particular genus of *Mollicutes* is
- 2        *Mycoplasma* or *Acholeplasma*.
  
- 1        9. The method of claim 8, wherein the particular species is selected from the
- 2        group consisting of *Acholeplasma laidlawii*, *Mycoplasma fermentans*,
- 3        *Mycoplasma hyorhinis*, *Mycoplasma orale*, *Mycoplasma arginini*, *Mycoplasma*
- 4        *pirum*, *Mycoplasma hominis*, and *Mycoplasma salivarium*.
  
- 1        10. The method of claim 9, wherein the particular species is *A. laidlawii*.
  
- 1        11. A mycoplasma test kit for detection of the presence of an amplified target
- 2        segment of nucleic acid in a nucleic acid mixture by use of a two stage
- 3        polymerase chain reaction, comprising:
  - 4            a first vessel containing a first stage PCR primer set which comprises
  - 5            single sequence primers complementary to said nucleic acid including

6        5'(AAAGTGGGCAATACCCAACGC)3' (SEQ ID NO:23), and  
7        5'(TCACGCTTAGATGCTTCAGCG)3' (SEQ ID NO:24), and  
8        at least one of a first mixed sequence primer set including primers  
9        complementary to said nucleic acid selected from the group consisting of  
10       5'(ACACCATGGGAGCTGGTAAT)3' (SEQ ID NO:1), and  
11       5'(ACACCATGGGAGTTGGTAAT)3' (SEQ ID NO:2), and  
12       at least one of a second mixed sequence primer set including primers  
13       complementary to said nucleic acid selected from the group consisting of  
14       5'(CTTCATCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:19),  
15       5'(CTTCTTCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:22),  
16       5'(CTTCATCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:21), and  
17       5'(CTTCTTCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:20);  
18       a second vessel containing a second stage PCR primer set which comprises  
19       a single sequence primer complementary to said nucleic acid having the  
20       sequence  
21       5'(CCACTGTGTGCCCTTGTTCC)3' (SEQ ID NO: 25), and  
22       at least one of a first mixed sequence primer set including primers  
23       complementary to said nucleic acid selected from the group consisting of  
24       5'(GTGCGGATGGATCACCTCCT)3' (SEQ ID NO:7),  
25       5'(GTGGGGCTGGATCACCTCCT)3' (SEQ ID NO:10),  
26       5'(GTGCGGCTGGATCACCTCCT)3' (SEQ ID NO:9), and  
27       5'(GTGGGGATGGATCACCTCCT)3' (SEQ ID NO:8), and  
28       at least one of a second mixed sequence primer set including primers  
29       complementary to said nucleic acid selected from the group consisting of  
30       5'(GCATCCACCAAAACCCCTT)3' (SEQ ID NO:11),  
31       5'(GCATCCACCAAAACTCTT)3' (SEQ ID NO:15),  
32       5'(GCATCCACCAAAATACCCTT)3' (SEQ ID NO:13),  
33       5'(GCATCCACCAAAATACTCTT)3' (SEQ ID NO:16),  
34       5'(GCATCCACCAAAACCCCTT)3' (SEQ ID NO:12),

35        5'(GCATCCACCATAAACTCTT)3' (SEQ ID NO:17),  
36        5'(GCATCCACCATATAACCCTT)3' (SEQ ID NO:14), and  
37        5'(GCATCCACCATATACTCTT)3' (SEQ ID NO:18);  
38        a third vessel containing a first positive control nucleic acid; and  
39        a fourth vessel containing a second positive control nucleic acid.

1        12. The kit of claim 11 wherein said primers in said first and second stage PCR  
2        primer sets immediately flank a DNA segment diagnostic of a particular class,  
3        genus, species or subspecies of microorganisms.

1        13. The kit of claim 12, wherein the particular class of microorganism is  
2        *Mollicutes*.

1        14. The kit of claim 13, wherein the particular genus of *Mollicutes* is  
2        *Mycoplasma* or *Acholeplasma*.

1        15. The kit of claim 14, wherein the particular species is selected from the group  
2        consisting of *Acholeplasma laidlawii*, *Mycoplasma fermentans*, *Mycoplasma*  
3        *hyorhinis*, *Mycoplasma orale*, *Mycoplasma arginini*, *Mycoplasma pirum*,  
4        *Mycoplasma hominis*, and *Mycoplasma salivarium*.

1        16. The kit of claim 15 wherein the particular species is *Acholeplasma laidlawii*.

1        17. A first stage PCR primer set for amplifying a target segment of nucleic acid  
2        in a sample nucleic acid mixture which comprises:  
3                single sequence primers complementary to said nucleic acid including  
4                5'(AAAGTGGGCAATACCCAACGC) 3' (SEQ ID NO:23), and  
5                5'(TCACGCTTAGATGCTTCAGCG)3' (SEQ ID NO:24); and  
6                at least one of a first mixed sequence primer set including primers

7 complementary to said nucleic acid selected from the group consisting of  
8 5'(ACACCATGGGAGCTGGTAAT)3' (SEQ ID NO:1), and  
9 5'(ACACCATGGGAGTTGGTAAT)3' (SEQ ID NO:2), and  
10 at least one of a second mixed sequence primer set including primers  
11 complementary to said nucleic acid selected from the group consisting of  
12 5'(CTTCATCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO: 19),  
13 5'(CTTCTTCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:22),  
14 5'(CTTCATCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:21), and  
15 5'(CTTCTTCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:20).

1 18. A second stage PCR primer set for amplifying a target segment of nucleic  
2 acid in a sample nucleic acid mixture which comprises:  
3 a single sequence primer complementary to said nucleic acid having the  
4 sequence  
5 5'(CCACTGTGTGCCCTTGTTCC)3' (SEQ ID NO:25); and  
6 at least one of a first mixed sequence primer set including primers  
7 complementary to said nucleic acid selected from the group consisting of  
8 5'(GTGCGGATGGATCACCTCCT)3' (SEQ ID NO:7),  
9 5'(GTGGGGCTGGATCACCTCCT)3' (SEG ID NO:10),  
10 5'(GTGCGGCTGGATCACCTCCT)3' (SEQ ID NO:9), and  
11 5'(GTGGGGATGGATCACCTCCT)3' (SEQ ID NO:8); and  
12 at least one of second mixed sequence primer set including primers  
13 complementary to said nucleic acid selected from the group consisting of  
14 5'(GCATCCACCAAAAAACCCCTT)3' (SEQ ID NO:11),  
15 5'(GCATCCACCAAAAAACTCTT)3' (SEQ ID NO:15),  
16 5'(GCATCCACCAAAATACCCCTT)3' (SEQ ID NO:13),  
17 5'(GCATCCACCAAAATACTCTT)3' (SEQ ID NO:16),  
18 5'(GCATCCACCAATAACCCCTT)3' (SEQ ID NO:12),  
19 5'(GCATCCACCAATAACTCTT)3' (SEQ ID NO:17),

20 5'(GCATCCACCATAACCCTT)3' (SEQ ID NO:14), and  
21 5'(GCATCCACCATAACTCTT)3' (SEQ ID NO:18).

1 19. The first stage PCR primer set of Claim 17, comprising:  
2 5'(ACACCATGGGAGCTGGTAAT)3' (SEQ ID NO:1),  
3 5'(ACACCATGGGAGTTGGTAAT)3' (SEQ ID NO:2),  
4 5'(AAAGTGGGCAATAACCAACGC)3' (SEQ ID NO:23),  
5 5'(CTTCATCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:19),  
6 5'(CTTCTTCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:22),  
7 5'(CTTCATCGACTTCAGACCCAAGGCAT)3' (SEQ ID NO:21),  
8 5'(CTTCTTCGACTTCCAGACCCAAGGCAT)3' (SEQ ID NO:20), and  
9 5'(TCACGCTTAGATGCTTCAGCG)3' (SEQ ID NO:24).

1 20. The second stage PCR primer set of claim 18, comprising:  
2 5'(GTGCGGATGGATCACCTCCT)3' (SEQ ID NO:7),  
3 5'(GTGGGGCTGGATCACCTCCT)3' (SEQ ID NO:10),  
4 5'(GTGCGGCTGGATCACCTCCT)3' (SEQ ID NO:9),  
5 5'(GTGGGGATGGATCACCTCCT)3' (SEQ ID NO:8),  
6 5'(GCATCCACCAAAAAACCCCTT)3' (SEQ ID NO:11),  
7 5'(GCATCCACCAAAAAACTCTT)3' (SEQ ID NO:15),  
8 5'(GCATCCACCAAAATACCCCTT)3' (SEQ ID NO:13),  
9 5'(GCATCCACCAAAATACCT)3' (SEQ ID NO:16),  
10 5'(GCATCCACCAATAACCCCTT)3' (SEQ ID NO:12),  
11 5'(GCATCCACCATACCCCTT)3' (SEQ ID NO:17),  
12 5'(GCATCCACCATACCCCTT)3' (SEQ ID NO:14),  
13 5'(GCATCCACCATACCT)3' (SEQ ID NO: 18) and  
14 5'(CCACTGTGTGCCCTTGTCCT)3' (SEQ ID NO:25).

1 21. A method for amplifying a target segment of nucleic acid in a sample  
2 nucleic acid mixture by performing a two stage polymerase chain reaction (PCR)  
3 to selectively amplify a nucleic acid comprising said target segment of nucleic  
4 acid of said sample nucleic acid mixture, wherein said method comprises the steps  
5 of:

6 a) adding a mixture of first stage predetermined primers to a sample  
7 nucleic acid mixture, wherein said first stage predetermined primers mixture  
8 comprises at least one mixed sequence oligonucleotide and at least one single  
9 sequence oligonucleotide, in order to amplify a nucleic acid flanked by said first  
10 stage predetermined primers and containing said target segment;  
11 b) repetitively performing polymerase chain reaction;  
12 c) adding a mixture of second stage predetermined primers to said  
13 sample nucleic acid mixture, wherein said second stage predetermined primers  
14 mixture comprises at least one single sequence oligonucleotide and at least one  
15 mixed sequence oligonucleotide, in order to selectively amplify said nucleic acid  
16 flanked by said second stage predetermined primers and comprising said target  
17 segment of nucleic acid; and  
18 d) repetitively performing polymerase chain reaction.

1 22. A mycoplasma test kit for detection of the presence of an amplified target  
2 segment of a nucleic acid in a nucleic acid mixture by use of two stage  
3 polymerase chain reaction, comprising a plurality of vessels, wherein:

4 a) a first vessel contains a mixture of first stage predetermined  
5 primers, and wherein said first stage predetermined primers mixture comprises at  
6 least one single sequence oligonucleotide and at least one mixed sequence  
7 oligonucleotide,  
8 b) a second vessel contains a mixture of second stage predetermined  
9 primers, wherein said second stage predetermined primers mixture comprises at  
10 least one single sequence oligonucleotide and at least one mixed sequence

- 11      oligonucleotide;
- 12            c)      a third vessel contains a first positive control nucleic acid; and
- 13            d)      a fourth vessel contains a second positive control nucleic acid.

1/3




FIG.1




FIG.2




FIG.3

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/07116

## A. CLASSIFICATION OF SUBJECT MATTER

IPC(6) :C12Q 1/68; C12P 19/34; C07H 21/04

US CL :435/6, 91.2; 536/24.3, 24.32, 24.33

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2; 536/24.3, 24.32, 24.33

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

Please See Extra Sheet.

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y, P	US 5,427,909 A (OKAMOTO ET AL.) 27 June 1995 (27.06.95), see entire document.	21-22
--		-----
A, P		1-20
Y	US 5,340,728 A (GROSZ ET AL.) 23 August 1994 (23.08.94), see abstract.	21-22
--		-----
A		1-20
Y	R. HARASAWA. 'Sensitive Detection of Mycoplasma in Cell Cultures by using Two-Step Polymerase Chain Reaction.' In: Rapid Diagnosis of Mycoplasmas. Edited by I. Kahane. New York: Plenum Publishing Corporation, 1993, pages 227-232, see entire article.	21-22
--		-----
A		1-20



Further documents are listed in the continuation of Box C.



See patent family annex.

* Special categories of cited documents:	"T"	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"A" document defining the general state of the art which is not considered to be of particular relevance	"X"	document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"E" earlier document published on or after the international filing date	"Y"	document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&"	document member of the same patent family
"O" document referring to an oral disclosure, use, exhibition or other means		
"P" document published prior to the international filing date but later than the priority date claimed		

Date of the actual completion of the international search

21 JULY 1996

Date of mailing of the international search report

02 AUG 1996

Name and mailing address of the ISA/US  
Commissioner of Patents and Trademarks  
Box PCT  
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

DIANNE REES

Telephone No. (703) 308-0196

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/07116

## C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 92/05280 A1 (IMPERIAL CANCER RESEARCH TECHNOLOGY LIMITED) 02 April 1992 (02.04.92), see abstract.	21-22
--		-----
A		1-20
Y	JP 4-004,899 A (TAKARA SHUZO KK) 09 January 1992 (09.01.92), see pages 706-709.	21-22
--		-----
A		1-20
Y	JP 3-254,700 A (TAKARA SHUZO KK) 13 November 1991 (13.11.91), see page 756-757.	21-22
--		-----
A		1-20
Y	JP 3-161,000 A (TAKARA SHUZO KK) 10 July 1991 (10.07.91), see page 713.	21-22
--		-----
A		1-20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US96/07116

**B. FIELDS SEARCHED**

Electronic data bases consulted (Name of data base and where practicable terms used):

APS, AIDSLINE, BIOSIS, BIOTECHABS, BIOTECHDS, CANCERLIT, EMBASE, SCISEARCH, USPATFULL,  
WPIDS, JAPIO  
search terms: mixed or degenerate primers, type specific, strain specific or single sequence primers, nested or two stage  
PCR, Mycoplasma, SEQ. ID. NOs.